Abstract
In the anterior pituitary besides the classical tropic hormones, peptides of a small molecular weight are also synthesized. One of them is the vasoactive intestinal polypeptide (VIP). VIP immunoreactivity is readily detected in human and monkey pituitaries; however, in the rat VIP immunoreactive cells were observed in about 50% of intact rats. In estrogen treated rats VIP immunoreactive cells were observed in the anterior pituitary of all animals. In this work, we have examined the effect of long-term sexual steroid treatments on the VIP immunoreactivity of the anterior pituitary using diethylstilbestrol (DES) or progesterone (P) filled capsules. The effectiveness of steroid treatments was tested by the measurement of plasma prolactin (PRL) level and by the appearance of prolactinoma. DES enhanced the plasma PRL level and 5 months later it induced prolactinomas, the concomitant P treatment prevented both the elevation of plasma PRL level and the formation of prolactinomas. These results indicated that there was enough steroid in the capsules. There was a positive correlation between the duration of DES influence and the number of VIP immunoreactive cells. Two months after the implantation of DES there was a considerable number of VIP cells in the anterior pituitary, and 5 months after implantation the number of VIP cells was greatly increased so as to form a VIP-oma. Concomitant implantation of P prevented the formation of VIP-oma. Two months after the implantation, the DES capsule was removed. Already 2 months after removal the number of VIP cells approximated to the control level. It has been concluded that P can prevent the undesired effect of DES not only on the PRL, but on the VIP immunoreactivity as well.
Similar content being viewed by others
Abbreviations
- DES:
-
Diethylstilbestrol
- E:
-
Estrogen
- E2:
-
Estradiol
- ECAP:
-
Empty capsule
- ER:
-
Estrogen receptor
- FSCs:
-
Folliculostellate cells
- FSH:
-
Follicle stimulating hormone
- ir:
-
Immunoreactive
- LH:
-
Luteinizing hormone
- P:
-
Progesterone
- PR:
-
Progesterone receptor
- PRL:
-
Prolactin
- VIP:
-
Vasoactive intestinal polypeptide
References
W.W. Morgan, R.W. Steger, M.S. Smith, A. Bartke, C.A. Sweeney, Endocrinology 116, 17–24 (1985)
S. Koike, M. Sakai, M. Muramatsu, Nucleic Acids Res. 15, 2499–2513 (1987)
G.G.J.M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J.A. Gustaffsson, Proc. Natl. Acad. Sci. USA 93, 5925–5930 (1996)
M. Gonzales, R. Reyes, C. Damas, R. Alonso, A.R. Bello, Gen. Comp. Endocrinol. 155, 857–868 (2008)
M.E. Wilson, R.H. Price Jr., R.J. Handa, Endocrinology 139, 5151–5156 (1998)
M. Szabó, S.M. Kilen, S.J. Nho, N.B. Schwartz, Biol. Reprod. 62, 95–102 (2000)
J.C. Garrido-Gracia, A. Gordon, C. Bellido, R. Aguilar, I.I. Barranco, Y. Millán, J.M. de Las Mulas, J.E. Sánchez-Criado, J. Endocrinol. 193, 107–119 (2007)
R.D. Brinton, R.F. Thompson, M.R. Roy, M. Baudry, Y.M. Wang, C.E. Finch, T.E. Morgan, C.J. Pike, W.J. Mack, F.Z. Stanczyk, J. Nilsen, Front. Neuroendocrinol. 29, 313–339 (2008)
C. Guerra-Araiza, M.A. Cerbon, S. Morimoto, I. Camacho-Arroyo, Life Sci. 66, 1743–1752 (2000)
C. Leranth, N.J. Maclusky, T.J. Brown, E.C. Chen, D.E. Redmond Jr, F. Naftolin, Neuroendocrinology 55, 667–682 (1992)
I. Merchenthaler, M.L. Lane, S. Numan, T.L. Dellovade, J. Comp. Neurol. 473, 270–291 (2004)
H. Houben, C. Denef, Peptides 15, 547–582 (1994)
S. Reichlin, Ann. N. Y. Acad. Sci. 527, 431–449 (1988)
D.W. Hsu, P.N. Riskind, E.T. Hedley-Whyte, Am. J. Pathol. 135, 329–338 (1989)
K. Köves, P.E. Gottschall, T.J. Görcs, J.G. Schammell, A. Arimura, Endocrinology 126, 1756–1763 (1990)
G.M. Nagy, J.J. Mulchahey, J.D. Neill, Endocrinology 122, 346–366 (1988)
J.W. Goldzieher, Perspect. Biol. Med. 36, 363–368 (1993)
R. Kurzrok, J. Contracept. 2, 27–29 (1937)
W.D. Müller-Janncke, Z. Gesamte, Inn. Med. 43, 420–422 (1988)
L.M. Senturk, C.T. Erel, Curr. Opin. Obstet. Gynecol. 20, 221–228 (2008)
J. Szekeres-Bartho, J. Balasch, Hum. Reprod. Update 14, 27–35 (2008)
H. Burger, Climacteric 1, 11–36 (2003)
L.J. Tivis, N.A. Ceballos, G. Chastain, R.D. Tivis, Neuropsychobiology 58, 104–110 (2008)
W.H. Utiah, D.F. Archer, G.A. Bachmann, C. Gallagher, F. Grodstein, J.R. Heiman, Menopause 15, 584–602 (2008)
W.K. Oh, Clin. Prostate Cancer 1, 81–89 (2002)
W.H. Rosténe, Prog. Neurobiol. 22, 103–129 (1984)
T.C. Hagen, I.M.A. Arnaout, W.J. Scherzer, D.R. Martinson, T.C. Garthwaite, Neuroendocrinology 43, 641–645 (1986)
J. Carretero, M. Angoso, M. Rubio, E.J. Blanco, E. Sierra, J.J. Herrero, E. Perez, D.J. Burks, Anat. Embryol. 211, 11–18 (2006)
K. Köves, I-Li Chen, T.J. Görcs, J. Scammell, A. Arimura, Endocrine 5, 219–223 (1996)
R.A. Prysor-Jones, J.J. Silverlight, J.S. Jenkins, Neurosci. Lett. 80, 333–338 (1987)
J.A. Balsa, F. Sanchez-Franco, M.J. Lorenzo, F. Pazos, J.I. Lara, L. Cacicedo, Endocrinology 13, 508–513 (1996)
O. Gómez, J.A. Balsa, Endocrinology 144, 4403–4409 (2003)
O. Gómez, J.A. Balsa, Neuroendocrinology 80, 324–331 (2004)
A. Heinzlmann, K. Köves, Endocrine 33, 342–348 (2008)
J.J. Calderon, T.G. Muldoon, V.B. Mahesh, Endocrinology 120, 2428–2435 (1987)
J.H. Casas, M.C. Chang, Biol. Reprod. 2, 315–325 (1970)
J.E. DeMaria, J.D. Livingston, M.E. Freeman, Brain Res. 879, 139–147 (2000)
A. Gulyás, T.J. Görcs, T. Freund, Neuroscience 37, 31–44 (1990)
Acknowledgments
The authors are greatly indebted to Ildikó Schay for her proofreading. This work was supported by the Department of Human Morphology and Developmental Biology and by the Hungarian Research Grant (OTKA-68170) to GMN.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heinzlmann, A., Köves, K. & Nagy, G.M. Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities. Endocr 37, 396–402 (2010). https://doi.org/10.1007/s12020-010-9320-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-010-9320-x